Biocodex and ATHOS led a €55m Series B round in MRM Health.

Biocodex, an independent French pharmaceutical group, and ATHOS, a Munich-based single family office, led a €55m Series B round in MRM Health, a clinical-stage biopharmaceutical company. “This funding marks a pivotal moment for MRM Health. With the support of our experienced international investor syndicate, we are now well positioned to deliver transformative therapies for patients with chronic inflammatory diseases, where current treatments often fall short. Our CORAL® platform gives us a unique edge in designing potent, resilient and scalable microbiome-based therapeutics. This new funding will allow us to further build both our platform and pipeline,” Sam Possemiers, MRM Health CEO.